Pfizer vaccine not coming to India soon as trials yet to be conducted

Pfizer vaccine not coming to India soon as trials yet to be conducted

While the UK government has cleared Pfizer-BioNTech’s mRNA vaccine for use in public, the same is unlikely to be available anytime soon in India.

For one, US giant Pfizer’s India arm has not yet applied for conducting here, according to sources, and secondly, the vaccine has stringent temperature requirements (-75 degree Celsius), which make it unviable for cold-chain logistics in India.

A government official in the know indicated that Pfizer has not yet applied for holding on Indian volunteers, as is a pre-requisite for the regulator here to give authorisation to a particular investigational drug or vaccine.

AstraZeneca-Oxford vaccine is being tested in a phase-3 trial on over 1,600 subjects in India by Serum Institute. So, is the Sputnik V, developed by Russia. It is being tested on Indians by Dr. Reddy’s Laboratories.

“Pfizer’s phase-3 study has enrolled 43,358 participants with 42 per cent having diverse backgrounds. It will be making this data available to governments across the world to seek regulatory approvals. Once we have a go-ahead from the government, we will work with the authorities to determine the pathway required for deployment in India. The goal will be to ensure that an efficacious and safe vaccine is available for deployment in the country,” said a Pfizer spokesperson.

The government official did clarify that India was in touch with MNC players and Pfizer is one of them. V K Paul, member-health, NITI Aayog, and chairman of the panel on vaccine administration, had earlier indicated that the government feels Pfizer’s limited number of doses would not be enough to meet India’s demand.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor